Search research articles
Contact Us
Filters
Showing results (91-100 of 124) with videos related to
Page
of 13
Sort By:
Clinical Pharmacology and Therapeutics
|
September 1, 1984
Ceftazidime disposition in acute and stable cystic fibrosis
J S Leeder, M Spino, A F Isles, et al.
Clinical Pharmacology and Therapeutics
|
May 26, 1999
Investigation of terbinafine as a CYP2D6 inhibitor in vivo
S M Abdel-Rahman, R R Gotschall, R E Kauffman, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals
|
July 27, 2016
Bioactivation of Trimethoprim to Protein-Reactive Metabolites in Human Liver Microsomes
Jennifer L Goldman, Yakov M Koen, Steven A Rogers, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals
|
June 29, 1999
Potent inhibition of cytochrome P-450 2D6-mediated dextromethorphan O-demethylation by terbinafine
S M Abdel-Rahman, K Marcucci, T Boge, et al.
Canadian Journal of Physiology and Pharmacology
|
November 8, 2001
Cytochrome P4502C9 (CYP2C9) allele frequencies in Canadian Native Indian and Inuit populations
A Gaedigk, W L Casley, R F Tyndale, et al.
Pharmacogenetics
|
January 14, 2000
Optimization of cytochrome P4502D6 (CYP2D6) phenotype assignment using a genotyping algorithm based on allele frequency data
A Gaedigk, R R Gotschall, N S Forbes, et al.
Clinical Pharmacokinetics
|
July 1, 1985
Cerebrospinal fluid pharmacokinetics of tobramycin, ceftazidime, phenobarbitone and phenytoin in a child
G Koren, S Lavi, M Greenwald, et al.
Leukemia & Lymphoma
|
September 1, 1992
Growth of human lymphoma cells in SCID mice
H Chang, S Leeder, V A Cook, et al.
Clinical Pharmacology and Therapeutics
|
November 1, 2007
The CYP2D6 activity score: translating genotype information into a qualitative measure of phenotype
A Gaedigk, S D Simon, R E Pearce, et al.
Pharmacogenetics
|
September 10, 1998
NAD(P)H:quinone oxidoreductase: polymorphisms and allele frequencies in Caucasian, Chinese and Canadian Native Indian and Inuit populations
A Gaedigk, R F Tyndale, M Jurima-Romet, et al.
Page
of 13
Search research articles
Search
Showing results (91-100 of 124) with videos related to
Sort By:
Page
of 13
Clinical Pharmacology and Therapeutics
|
September 1, 1984
Ceftazidime disposition in acute and stable cystic fibrosis
J S Leeder, M Spino, A F Isles, et al.
Clinical Pharmacology and Therapeutics
|
May 26, 1999
Investigation of terbinafine as a CYP2D6 inhibitor in vivo
S M Abdel-Rahman, R R Gotschall, R E Kauffman, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals
|
July 27, 2016
Bioactivation of Trimethoprim to Protein-Reactive Metabolites in Human Liver Microsomes
Jennifer L Goldman, Yakov M Koen, Steven A Rogers, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals
|
June 29, 1999
Potent inhibition of cytochrome P-450 2D6-mediated dextromethorphan O-demethylation by terbinafine
S M Abdel-Rahman, K Marcucci, T Boge, et al.
Canadian Journal of Physiology and Pharmacology
|
November 8, 2001
Cytochrome P4502C9 (CYP2C9) allele frequencies in Canadian Native Indian and Inuit populations
A Gaedigk, W L Casley, R F Tyndale, et al.
Pharmacogenetics
|
January 14, 2000
Optimization of cytochrome P4502D6 (CYP2D6) phenotype assignment using a genotyping algorithm based on allele frequency data
A Gaedigk, R R Gotschall, N S Forbes, et al.
Clinical Pharmacokinetics
|
July 1, 1985
Cerebrospinal fluid pharmacokinetics of tobramycin, ceftazidime, phenobarbitone and phenytoin in a child
G Koren, S Lavi, M Greenwald, et al.
Leukemia & Lymphoma
|
September 1, 1992
Growth of human lymphoma cells in SCID mice
H Chang, S Leeder, V A Cook, et al.
Clinical Pharmacology and Therapeutics
|
November 1, 2007
The CYP2D6 activity score: translating genotype information into a qualitative measure of phenotype
A Gaedigk, S D Simon, R E Pearce, et al.
Pharmacogenetics
|
September 10, 1998
NAD(P)H:quinone oxidoreductase: polymorphisms and allele frequencies in Caucasian, Chinese and Canadian Native Indian and Inuit populations
A Gaedigk, R F Tyndale, M Jurima-Romet, et al.
Page
of 13